CG Oncology, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.23M | 5.07M | 4.04M | 2.17M | 551.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.23M | 5.07M | 4.04M | 2.17M | 551.00K |
| Cost of Revenue | 167.76M | 140.51M | 121.29M | 115.06M | 105.22M |
| Gross Profit | -161.54M | -135.44M | -117.25M | -112.89M | -104.67M |
| SG&A Expenses | 91.08M | 79.52M | 73.53M | 67.24M | 52.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 258.85M | 220.03M | 194.81M | 182.30M | 157.84M |
| Operating Income | -252.62M | -214.96M | -190.77M | -180.12M | -157.29M |
| Income Before Tax | -224.38M | -186.75M | -161.00M | -151.48M | -128.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -224.38 | -186.75 | -161.00 | -151.48 | -128.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -224.38M | -186.75M | -161.00M | -151.48M | -128.08M |
| EBIT | -252.62M | -214.96M | -190.77M | -180.12M | -157.29M |
| EBITDA | -249.66M | -212.70M | -189.33M | -179.53M | -157.09M |
| EPS Basic | -2.70 | -2.34 | -2.08 | -2.03 | -1.76 |
| Normalized Basic EPS | -1.68 | -1.46 | -1.30 | -1.27 | -1.10 |
| EPS Diluted | -2.70 | -2.34 | -2.08 | -2.03 | -1.76 |
| Normalized Diluted EPS | -1.68 | -1.46 | -1.30 | -1.27 | -1.10 |
| Average Basic Shares Outstanding | 329.51M | 317.54M | 309.21M | 298.20M | 288.61M |
| Average Diluted Shares Outstanding | 329.51M | 317.54M | 309.21M | 298.20M | 288.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |